X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

BioPh China 2016 awaits your participation in June

Yuvraj_pawp by Yuvraj_pawp
22nd February 2016
in Asia, News

BioPh China 2016, hosted by UBM EMEA and China Chamber of Commerce of Medicines & Health Products Importers & Exporters and co-organized by UBM Sinoexpo, will be held on 21 – 23 June 2016 at Hall E2 in Shanghai New International Expo Centre.

 

The emerging industry of bio-medicine has become one of the strategic directions and focal development points of the pharmaceutical industry in coming years. This focus is supported by number of factors: recent completion of the Development of Pharmaceutical Industry for the Thirteenth Five-Year Plan Period in 2015, as well as by Made in China 2025 listing biomedicine represented by gene drugs, monoclonal antibody/protein drugs and vaccines as one of the ten key sectors to be develop in the future. The improvement of the overall technological content, added economic value of bio-medical industry, fostering of innovative drugs account to further contributing factors.

 

With biomedicine being one of the highlights at Nobel Prize and Prix Galien Awards, it is undoubted that biomedical industry has entered another fast growing golden age. As an annual professional biopharmaceutical technology event highly anticipated in Asian-Pacific region, BioPh China has receivedmore focus from European and US countries over the past years. BioPh China will take place in 2016 providing a one-stop trade, exchange and learning platform for biopharmaceutical industry, bringing you the latest biomedical R&D achievements and technologies.

 

Up to now, domesticpharmaceutical giants such asGan& Lee Pharmaceuticals, TonghuaDongbao, Shenzhen Mellow Hope and DongchengBiochemicals have all confirmed their participation at BioPh China 2016, showcasing the most advanced R&D achievements, technologies and solutions of biomedical technical fields, including protein, antigen, polypeptide, enzyme, bioprocessing, antibody, biological agent, bio-manufacturing, cell biology, clinical trial, new drug R&D, genomics, genetics, personalized medicine, stem cell research, therapeutics, vaccine, biofuel, nanotechnology, biological information, biological information technology, and platform technology.

 

To enhance the communication and cooperation between Chinese biomedical enterprises and international enterprises, the 3rdBioPh Summit China, as the most important concurrently held onsite event, will gather industry-university-research elites and leaders in biomedical industry to discuss the course for future development of the industry. The summit will focus on the recent dynamics of Chinese and foreign policies, and global market opportunities and other strategic topics, as well as Chinese and foreign latest research achievements in recombinant protein drugs, antibodies and vaccines, to provide industry practitioners with an excellent platform for sharing industry information, R&D experience and case analysis. BioPh China 2016 will merge the new thinking and concepts into the Chinese biomedical industry through linkage of “exhibition” and “conference”.

 

Online visitor registration is now open! Please visit http://www.cphi.com/china to register or contact Ms. Tina Zheng (tina.zheng@ubmsinoexpo.com) for more information.

Previous Post

Come to P-Logi 2016 to Experience the Latest Intelligent Pharmaceutical Logistics!

Next Post

Quality and Clean Room Microenvironment Created by Innovation: EP & Clean Tech China launches the Discovery Tour onAir Treatment

Related Posts

Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
Next Post

Quality and Clean Room Microenvironment Created by Innovation: EP & Clean Tech China launches the Discovery Tour onAir Treatment

Latest News

Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In